Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
Completed
Conditions studied: Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
In brief
The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).
Key facts
- Study ID
- NCT02948946
- Run by
- H. Lee Moffitt Cancer Center and Research Institute
- People needed
- 105
- Starts
- 2017-01-09
- Expected to finish
- 2020-09-15
- Last updated by the study team
- 2021-08-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- NET Cohort-
- Patients with histologically or cytologically proven diagnosis of any grade, any stage NET of GEP or lung origin; In the first stage of the study (initial 50 patients) only patients with stage IV, well-differentiated tumors (G1/G2) will be enrolled.
- Patients with stable or progressive disease, as documented on a scan (CT, MRI); Progression status will be documented on case report form (CRF).
- Allowed prior therapies include: a.) Surgery (tumor surgery at least four weeks prior to study entry); b.) Locoregional therapy such as: chemoembolization, radio-embolization, radiofrequency ablation, radiotherapy at least six weeks prior to study entry; c.) Any number of previous lines of systemic therapy, providing that cytotoxic therapies (chemotherapy, PRRT) have been discontinued at least 4 weeks prior to study entry.
- Non-NET Cohort -
- Healthy participants
- Patients with histologically or cytologically proven diagnosis of any grade, any stage GI malignancies.
You may not qualify if…
- NET Cohort -
- Patients on treatment with cytotoxic agents (chemotherapy, PRRT).
- Patients with renal insufficiency or congestive heart failure.
- No other active malignancy within 3 years of enrolment except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission.
- Non-NET Cohort
- Patients with GI malignancies with neuroendocrine differentiation.
Where it is running
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.